Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Clene Inc. (CLNN)

1.65   0.03 (1.85%) 02-03 15:40
Open: 1.64 Pre. Close: 1.62
High: 1.67 Low: 1.62
Volume: 92,637 Market Cap: 122(M)

Technical analysis

as of: 2023-02-03 3:16:11 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 1.98     One year: 2.31
Support: Support1: 1.21    Support2: 0.92
Resistance: Resistance1: 1.7    Resistance2: 1.98
Pivot: 1.51
Moving Average: MA(5): 1.58     MA(20): 1.4
MA(100): 1.45     MA(250): 2.4
MACD: MACD(12,26): 0.1     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 84.7     %D(3): 80.8
RSI: RSI(14): 66.6
52-week: High: 5.13  Low: 0.87
Average Vol(K): 3-Month: 177 (K)  10-Days: 125 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CLNN ] has closed below upper band by 15.1%. Bollinger Bands are 40.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.68 - 1.69 1.69 - 1.69
Low: 1.58 - 1.59 1.59 - 1.6
Close: 1.61 - 1.62 1.62 - 1.63

Company Description

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Headline News

Mon, 23 Jan 2023
Clene Inc. (NASDAQ:CLNN) Sees Large Drop in Short Interest - MarketBeat

Wed, 18 Jan 2023
Private companies are Clene Inc.'s (NASDAQ:CLNN) biggest owners and were rewarded after market cap rose by US$29m last week - Simply Wall St

Wed, 11 Jan 2023
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23 - Marketscreener.com

Sun, 08 Jan 2023
These 10 Stocks Had The Most Insider Buying Activity During The ... - Nasdaq

Wed, 28 Dec 2022
Clene's COVID-19 Candidate Shows No Substantial Symptom Resolution In Phase 2 Trial - Yahoo Finance

Mon, 03 Oct 2022
Clene Stock Falls As Lead Asset Fails To Show Survival, Function Benefit In Amyotrophic Lateral Sclerosis Trial - Yahoo Finance

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 74 (M)
% Held by Insiders 2.558e+007 (%)
% Held by Institutions 62 (%)
Shares Short 2,410 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.986e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -11
Return on Assets (ttm) 596.7
Return on Equity (ttm) -58.3
Qtrly Rev. Growth 438000
Gross Profit (p.s.) 323.33
Sales Per Share 0
EBITDA (p.s.) 2.41111e+006
Qtrly Earnings Growth 0.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -41 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -1.98

Stock Dividends

Dividend 0
Forward Dividend 2.26e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.